Publications

Notable Publications

Wyrobnik, I., Steinberg, M., Gelfand, A., Rosenblum, R., Eid Mutlak, Y., Sulimani, L., Procaccia, S., Ofran, Y., Novak-Kotzer, H., and Meiri, D. (forthcoming 2023) “Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression”. Oncoimmunology.
Besser, E., Gelfand, A., Lewitus, G.M., Novak-Kotzer, H., Procaccia, S., Berman, P., Louria-Hayon, I., Shreiber-Livne, I., Ofran, Y. and Meiri, D. (2023) “Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia”. Cancer Communications 43(6).
Aviram, J., Lewitus, G. M., Vysotski, Y., Berman, P., Shapira, A., Procaccia, S., and Meiri, D. (2021) “Sex differences in medical cannabis-related adverse effects“. PAIN, 163(5), 975-983.
Berman, P., Sulimani, L., Gelfand, A., Amsalem, K., Lewitus, G. M., and Meiri, D. (2020) “Cannabinoidomics–An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome“. Talanta , 121336.
Baram, L., Peled, E., Berman, P., Yellin, B., Besser, E., Benami, M., Louria-Hayon, I., Lewitus, G.M. and Meiri, D. (2019) “The heterogeneity and complexity of Cannabis extracts as antitumor agents“. Oncotarget, 10(41), p.4091.
Berman P., Furoan K., M. Lewitus G., Mukha D., Benami M., Shlomi T., and Meiri D. (2018) “A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis“. Scientific Reports. 8(1):14280.

Full List of Publications (newest first)

2023

    • Shreiber-Livne, I., Sulimani, L., Shapira, A., Procaccia, S., Meiri, D.* and Sosnik, A.* (2023) “Poly(ethylene glycol)-b-poly(epsilon-caprolactone) nanoparticles as a platform for the improved oral delivery of cannabidiol”. Drug Delivery and Translational Research.
    • Wyrobnik, I., Steinberg, M., Gelfand, A., Rosenblum, R., Eid Mutlak, Y., Sulimani, L., Procaccia, S., Ofran, Y., Novak-Kotzer, H., and Meiri, D. (2023) “Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression”. Oncoimmunology.
    • Besser, E., Gelfand, A., Lewitus, G.M., Novak-Kotzer, H., Procaccia, S., Berman, P., Louria-Hayon, I., Shreiber-Livne, I., Ofran, Y. and Meiri, D. (2023) “Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia”. Cancer Communications 43(6).
    • Blal, K., Besser, E., Procaccia, S., Schwob, O., Lerenthal, Y., Abu Tair, J., Meiri, D. and Benny, O. (2023). The Effect of Cannabis Plant Extracts on Head and Neck Squamous Cell Carcinoma and the Quest for Cannabis-Based Personalized Therapy. Cancers, 15(2), p.497.
    • Waissengrin, B., Leshem, Y., Taya, M., Meiri, D., Merimsky, O., Shamai, S., Wolf, I. and Rubinek, T. (2023) The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?. European Journal of Cancer, 180, pp.52-61.

    2022

    • Stolar, O., Hazan, A., Vissoker, R.E., Kishk, I.A., Barchel, D., Lezinger, M., Dagan, A., Treves, N., Meiri, D., Berkovitch, M., Kohn, E., Heyman, E. (2022) Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Frontiers in Pharmacology 13:977484.
    • Yekhtin, Z., Khuja, I., Meiri, D., Or, R., and Almogi-Hazan, O. (2022). Differential effects of D9 tetrahydrocannabinol (THC)-and cannabidiol (CBD)-Based cannabinoid treatments on macrophage immune function in vitro and on gastrointestinal inflammation in a murine model. Biomedicines, 10(8), 1793.
    • Sznitman, S. R., Meiri, D., Amit, B. H., Rosenberg, D., and Greene, T. (2022) Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study. Journal of anxiety disorders, 92, 102632.
    • Uziel, A., Milay, L., Procaccia, S., Cohen, R., Burstein, A., Sulimani, … & Meiri, D. (2022) Solid-State Microwave Drying for Medical Cannabis Inflorescences: A Rapid and Controlled Alternative to Traditional Drying. Cannabis and Cannabinoid Research.
    • Aviram, J., Lewitus, G.M., Vysotski, Y., Amna, M., Ouryvaev, A., Procaccia, S., Cohen‏, I., Leibovici, A., Akria, L., Goncharov, D., Neomi Mativ, Kauffman, A., Bar-Sela, G.* and Meiri * (2022) “The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients”. Frontiers in Pain Research 70.
    • Dimitriou, I., Meiri, D., Jitkova, Y., Elford, A.R., Koritzinsky, M., Schimmer, … & Rottapel, R. (2022) Translational Control by 4E-BP1/2 Suppressor Proteins Regulates Mitochondrial Biosynthesis and Function during CD8 + T Cell Proliferation. The Journal of Immunology.
    • Procaccia, S., Lewitus, G. M., Lipson Feder, C., Shapira, A., Berman, P., & Meiri, D. (2022) Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug. Frontiers in Pharmacology, 1308.
    • Shlosberg, Y., Krupnik, N., Tóth, T. N., Eichenbaum, B., Meirovich, M. M., Meiri, D., … & Adir, N. (2022). Bioelectricity generation from live marine photosynthetic macroalgae. Biosensors and Bioelectronics, 198, 113824.

    2021

    • Sznitman, S. R., Rosenberg, D., Vulfsons, S., Meiri, D., & Greene, T. (2021). Medical Cannabis Use and Pain: An Experience Sampling Study. Frontiers in Psychiatry, 1897.
    • Lipson, C. F., Cohen, O., Shapira, A., Katzir, I., Peer, R., Guberman, O., … & Meiri, D. (2021). Fertilization Following Pollination Predominantly Decreases Phytocannabinoids Accumulation and Alters the Accumulation of Terpenoids in Cannabis Inflorescences. Frontiers in plant science, 12.
    • Aviram, J., Lewitus, G. M., Vysotski, Y., Berman, P., Shapira, A., Procaccia, S., & Meiri, D. (2021). Sex differences in medical cannabis-related adverse effects. PAIN, 163(5), 975-983.
    • Aviram, J., Lewitus, G. M., Pud, D., Procaccia, S., Berman, P., Yellin, B., … & Meiri, D. (2021). Specific phytocannabinoid compositions are associated with analgesic response and adverse effects in chronic pain patients treated with medical cannabis. Pharmacological Research, 169, 105651.
    • Naftali, T., Bar-Lev Schleider, L., Almog, S., Meiri, D., & Konikoff, F. M. (2021). Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomized controlled trial. Journal of Crohn’s and Colitis 15(11): 1799–1806.
    • Tartakover-Matalon, S., Azar, S., Meiri, D., Hadar, R., Nemirovski, A., Abu Jabal, N., Konikoff, F.M., Drucker, L., Tam, J., and Naftali, T. (2021) Endocannabinoid Levels in Ulcerative-Colitis Patients Correlate with Clinical Parameters and are Affected by Cannabis Consumption. Frontiers in Endocrinology 12:685289.
    • Aviram, J., Lewitus, G. M., Vysotski, Y., Yellin, B., Berman, P., Shapira, A., & Meiri, D. (2021). Prolonged Medical Cannabis Treatment is Associated With Quality of Life Improvement and Reduction of Analgesic Medication Consumption in Chronic Pain Patients. Frontiers in pharmacology, 12: 613805.
    • Krupnik, N., Asis, D. T., Belkin, N., Rubin-Blum, M., Israel, Á., Paytan, A., … Meiri, D & Rahav, E. (2021). Dust-borne microbes affect Ulva ohnoi’s growth and physiological state. FEMS Microbiology Ecology, 97(3).
    • Aviram, J., Pud, D., Gershoni, T., Schiff‐Keren, B., Ogintz, M., Vulfsons, S., …Meiri, D. & Eisenberg, E. (2021). Medical cannabis treatment for chronic pain: Outcomes and prediction of response. European Journal of Pain, 25(2), 359-374.

    2020 and before

    • Hergenrather, J. Y., Aviram, J., Vysotski, Y., Campisi-Pinto, S., Lewitus, G. M., & Meiri, D. (2020). Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients. Rambam Maimonides medical journal, 11(1).
    • Aviram, J., Lewitus, G. M., Vysotski, Y., Uribayev, A., Procaccia, S., Cohen, I., … & Meiri, D. (2020). Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients. Pharmaceuticals, 13(12), 435.
    • Bar-Sela, G., Cohen, I., Campisi-Pinto, S., Lewitus, G. M., Oz-Ari, L., Jehassi, A., … & Wollner, M. (2020). Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers, 12(9), 2447.
    • Milay, L., Berman, P., Shapira, A., Guberman, O., & Meiri, D. (2020). Metabolic profiling of Cannabis secondary metabolites for evaluation of optimal postharvest storage conditions. Frontiers in plant science, 11.
    • Sznitman, S. R., Vulfsons, S., Meiri, D., & Weinstein, G. (2020). Medical cannabis and cognitive performance in middle to old adults treated for chronic pain. Drug and alcohol review.
    • Aviram, J., Pud, D., Gershoni, T., Schiff‐Keren, B., Ogintz, M., Vulfsons, S., … & Goor‐Aryeh, I. (2020). Medical Cannabis Treatment for Chronic Pain: Outcomes and Prediction of Response. European Journal of Pain.
    • McGarvey, P., Huang, J., McCoy, M., Orvis, J., Katsir, Y., Lotringer, N., … & Meiri, D. (2020). De novo assembly and annotation of transcriptomes from two cultivars of Cannabis sativa with different cannabinoid profiles. Gene, 145026.
    • Berman, P., Sulimani, L., Gelfand, A., Amsalem, K., Lewitus, G. M., & Meiri, D. (2020). Cannabinoidomics–An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome. Talanta , 121336.
    • Aviram, J., Vysotski, Y., Berman, P., Lewitus, G. M., Eisenberg, E., & Meiri, D. (2020). Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study. Brain Sciences, 10(6), 360.
    • Uziel, A., Gelfand, A., Amsalem, K., Berman, P., Lewitus, G. M., Meiri, D., & Lewitus, D. Y. (2020). Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect. ACS Applied Materials & Interfaces.
    • Sznitman, S. R., Vulfsons, S., Meiri, D., & Weinstein, G. (2020). Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study. BMJ Supportive & Palliative Care.
    • Shapira, A., Berman, P., Futoran, K., Guberman, O., & Meiri, D. (2019). Tandem mass spectrometric quantification of 93 terpenoids in Cannabis using static headspace (SHS) injections. Analytical chemistry.
    • Baram, L., Peled, E., Berman, P., Yellin, B., Besser, E., Benami, M., Louria-Hayon, I., Lewitus, G.M. and Meiri, D. (2019). The heterogeneity and complexity of Cannabis extracts as antitumor agents. Oncotarget, 10(41), p.4091.
    • Taha, T., Meiri, D., Talhamy, S., Wollner, M., Peer, A., & Bar‐Sela, G. (2019). Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. The oncologist, 24(4), 549-554.
    • Berman P., Furoan K., M. Lewitus G., Mukha D., Benami M., Shlomi T., Meiri D. (2018) A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Scientific Reports. 8(1):14280.

  • Previous Publications by D. Meiri

    • Mokady D., Meiri D. (2014) RhoGTPases- a novel link between cytoskeleton organization and cisplatin resistance. Drug Resistance Updates (impact factor 9.96).
    • Meiri D., Marshall CB., LaRose J., Gingras AC., Ikura M., Robert Rottapel. (2014) Mechanistic insight into the GPCR-mediated activation of the microtubule-associated RhoA-specific guanine exchange factor, GEF-H1. Nature Communications 11(5):4857.
    • Cullis J*., Meiri, D*., Radulovich N., LaRose J., Medrano M., Marcotte R., Marshall C.B.,  Moffat J., Neel B., Gingras AC., Robert Rottapel (2014) The RhoGEF GEF-H1 is required for RAS oncogene-driven pancreatic cancer. Cancer cell 25(2):181-95.
      *These authors contributed equally to the work.
    • Lighezan L., Meiri, D., Breiman A., Neagu A. (2013) Circular dichroism and the secondary structure of the ROF2 protein from Arabidopsis thaliana. J Biol Phys. 39(4):635-48.
    • Marshall, C.B., Meiri, D., Smith, M.J., Mazhab-Jafari, M.T., Gasmi-Seabrook, G.M., Rottapel R., Stambolic, V., and Ikura, M. (2012). Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts. Methods. 57, 473-85.
    • Meiri D., Marshall CB., Greeve, M.A., Bakal C., Kim B., Suarez F., LaRose J., Fine N.,  Ikura, M.,  and Rottapel R. (2011). Mechanistic insight into the microtubule and actin cytoskeleton coupling through dynein dependent RhoGEF inhibition. Mol Cell 45, 642-55.
    • Cohen-Peer R, Schuster S, Meiri D, Breiman A., and Avni A. (2010). Sumoylation of Arabidopsis heat shock factor A2 (HsfA2) modifies its activity during acquired thermotholerance. Plant Mol Biol 74, 33-45.
    • Meiri, D., Tazat, K., Cohen-Peer, R., Farchi-Pisanty, O., Aviezer-Hagai, K., Avni, A., and Breiman, A. (2010). Involvement of Arabidopsis ROF2 (FKBP65) in thermotolerance. Plant Mol Biol 72, 191-203.
    • Meiri, D., Greeve, M.A., Brunet, A., Finan, D., Wells, C.D., LaRose, J., and Rottapel, R. (2009). Modulation of Rho guanine exchange factor Lfc activity by protein kinase A-mediated phosphorylation. Mol Cell Biol. 29, 5963-5973.
    • Meiri, D. and Breiman, A. (2009). Arabidopsis ROF1 (FKBP62) modulates thermotolerance by interacting with HSP90.1 and affecting the accumulation of HsfA2-regulated sHSPs. Plant J. 59, 387-99